Literature DB >> 18180755

Family-based association of FKBP5 in bipolar disorder.

V L Willour1, H Chen, J Toolan, P Belmonte, D J Cutler, F S Goes, P P Zandi, R S Lee, D F MacKinnon, F M Mondimore, B Schweizer, J R DePaulo, E S Gershon, F J McMahon, J B Potash.   

Abstract

The FKBP5 gene product forms part of a complex with the glucocorticoid receptor and can modulate cortisol-binding affinity. Variations in the gene have been associated with increased recurrence of depression and with rapid response to antidepressant treatment. We sought to determine whether common FKBP5 variants confer risk for bipolar disorder. We genotyped seven tag single-nucleotide polymorphisms (SNPs) in FKBP5, plus two SNPs previously associated with illness, in 317 families with 554 bipolar offspring, derived primarily from two studies. Single marker and haplotypic analyses were carried out with FBAT and EATDT employing the standard bipolar phenotype. Association analyses were also conducted using 11 disease-related variables as covariates. Under an additive genetic model, rs4713902 showed significant overtransmission of the major allele (P=0.0001), which was consistent across the two sample sets (P=0.004 and 0.006). rs7757037 showed evidence of association that was strongest under the dominant model (P=0.001). This result was consistent across the two datasets (P=0.017 and 0.019). The dominant model yielded modest evidence for association (P<0.05) for three additional markers. Covariate-based analyses suggested that genetic variation within FKBP5 may influence attempted suicide and number of depressive episodes in bipolar subjects. Our results are consistent with the well-established relationship between the hypothalamic-pituitary-adrenal (HPA) axis, which mediates the stress response through regulation of cortisol, and mood disorders. Ongoing whole-genome association studies in bipolar disorder and major depression should further clarify the role of FKBP5 and other HPA genes in these illnesses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180755      PMCID: PMC4317355          DOI: 10.1038/sj.mp.4002141

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  40 in total

1.  Undetected genotyping errors cause apparent overtransmission of common alleles in the transmission/disequilibrium test.

Authors:  Adele A Mitchell; David J Cutler; Aravinda Chakravarti
Journal:  Am J Hum Genet       Date:  2003-02-13       Impact factor: 11.025

2.  A haplotype map of the human genome.

Authors: 
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

3.  Genomic survey of bipolar illness in the NIMH genetics initiative pedigrees: a preliminary report.

Authors: 
Journal:  Am J Med Genet       Date:  1997-05-31

4.  Daytime cortisol and stress reactivity in the offspring of parents with bipolar disorder.

Authors:  Mark A Ellenbogen; Sheilagh Hodgins; Claire-Dominique Walker; Sophie Couture; Sebastien Adam
Journal:  Psychoneuroendocrinology       Date:  2006-10-19       Impact factor: 4.905

5.  Validity of the assessment of bipolar spectrum disorders in the WHO CIDI 3.0.

Authors:  Ronald C Kessler; Hagop S Akiskal; Jules Angst; Margaret Guyer; Robert M A Hirschfeld; Kathleen R Merikangas; Paul E Stang
Journal:  J Affect Disord       Date:  2006-09-25       Impact factor: 4.839

6.  DST studies in psychotic depression: a meta-analysis.

Authors:  J C Nelson; J M Davis
Journal:  Am J Psychiatry       Date:  1997-11       Impact factor: 18.112

7.  Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders.

Authors:  S Modell; C J Lauer; W Schreiber; J Huber; J C Krieg; F Holsboer
Journal:  Neuropsychopharmacology       Date:  1998-04       Impact factor: 7.853

8.  Polymorphisms of the glucocorticoid receptor gene and major depression.

Authors:  Elisabeth F C van Rossum; Elisabeth B Binder; Matthias Majer; Jan W Koper; Marcus Ising; Sieglinde Modell; Daria Salyakina; Steven W J Lamberts; Florian Holsboer
Journal:  Biol Psychiatry       Date:  2006-04-15       Impact factor: 13.382

9.  The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders.

Authors:  I Heuser; A Yassouridis; F Holsboer
Journal:  J Psychiatr Res       Date:  1994 Jul-Aug       Impact factor: 4.791

10.  Increased waking salivary cortisol levels in young people at familial risk of depression.

Authors:  Zola N Mannie; Catherine J Harmer; Philip J Cowen
Journal:  Am J Psychiatry       Date:  2007-04       Impact factor: 18.112

View more
  56 in total

Review 1.  Genetics of emotion.

Authors:  Laura Bevilacqua; David Goldman
Journal:  Trends Cogn Sci       Date:  2011-08-10       Impact factor: 20.229

Review 2.  Gene-Stress-Epigenetic Regulation of FKBP5: Clinical and Translational Implications.

Authors:  Anthony S Zannas; Tobias Wiechmann; Nils C Gassen; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2015-08-13       Impact factor: 7.853

3.  Genome-wide association study of suicide attempts in mood disorder patients.

Authors:  Roy H Perlis; Jie Huang; Shaun Purcell; Maurizio Fava; A John Rush; Patrick F Sullivan; Steven P Hamilton; Francis J McMahon; Thomas G Schulze; Thomas Schulze; James B Potash; Peter P Zandi; Virginia L Willour; Brenda W Penninx; Dorret I Boomsma; Nicole Vogelzangs; Christel M Middeldorp; Marcella Rietschel; Markus Nöthen; Sven Cichon; Hugh Gurling; Nick Bass; Andrew McQuillin; Marian Hamshere; Nick Craddock; Pamela Sklar; Jordan W Smoller
Journal:  Am J Psychiatry       Date:  2010-11-01       Impact factor: 18.112

Review 4.  FKBP51 and FKBP52 in signaling and disease.

Authors:  Cheryl L Storer; Chad A Dickey; Mario D Galigniana; Theo Rein; Marc B Cox
Journal:  Trends Endocrinol Metab       Date:  2011-08-31       Impact factor: 12.015

5.  FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications.

Authors:  N C Gassen; J Hartmann; A S Zannas; A Kretzschmar; J Zschocke; G Maccarrone; K Hafner; A Zellner; L K Kollmannsberger; K V Wagner; D Mehta; S Kloiber; C W Turck; S Lucae; G P Chrousos; F Holsboer; E B Binder; M Ising; M V Schmidt; T Rein
Journal:  Mol Psychiatry       Date:  2015-04-07       Impact factor: 15.992

Review 6.  The molecular bases of the suicidal brain.

Authors:  Gustavo Turecki
Journal:  Nat Rev Neurosci       Date:  2014-10-30       Impact factor: 34.870

7.  DNA methylation and sex-specific expression of FKBP5 as correlates of one-month bedtime cortisol levels in healthy individuals.

Authors:  Richard S Lee; Pamela B Mahon; Peter P Zandi; Mary E McCaul; Xiaoju Yang; Utsav Bali; Gary S Wand
Journal:  Psychoneuroendocrinology       Date:  2018-07-04       Impact factor: 4.905

8.  FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

Authors:  Katarzyna A Ellsworth; Irene Moon; Bruce W Eckloff; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Joanna M Biernacka; Ryan Abo; Abra Brisbin; Yuan Ji; Scott Hebbring; Eric D Wieben; David A Mrazek; Richard M Weinshilboum; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

Review 9.  The role of FKBP5 in mood disorders: action of FKBP5 on steroid hormone receptors leads to questions about its evolutionary importance.

Authors:  John C O'Leary; Bo Zhang; John Koren; Laura Blair; Chad A Dickey
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

10.  Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study.

Authors:  David Brent; Nadine Melhem; Robert Ferrell; Graham Emslie; Karen Dineen Wagner; Neal Ryan; Benedetto Vitiello; Boris Birmaher; Taryn Mayes; Jamie Zelazny; Matthew Onorato; Bernie Devlin; Greg Clarke; Lynn DeBar; Marty Keller
Journal:  Am J Psychiatry       Date:  2009-12-15       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.